M edical device company Globus Medical (NYSE:GMED) in Q1 CY2025, with sales falling 1.4% year on year to $598.1 million. On the other hand, the company’s full-year revenue guidance of $2.85 ...

This article was originally published on Quiver News, read the full story. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

AUDUBON, Pa., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth ...

Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products. Meanwhile, the company’s series of product launches aid growth. The stock sports a Zacks ...

Globus Medical reports increased sales, optimistic 2025 outlook ...

Other than some upbeat news on new products being introduced, it has been rather quiet on the corporate front, with Globus Medical posting only the regular quarterly results. Second quarter sales ...

Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6.6% year on year to $657.3 million. The company expects ...